PSP/reg Biomarker Assay for Respiratory Infection Severity Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current biomarkers for detecting and managing lower respiratory tract infections, such as acute exacerbations of chronic obstructive pulmonary disease (COPD) and ventilator-associated pneumonia (VAP), are inadequate in predicting severity and prognosis.
Innovation Solution
Determining the level of pancreatic stone protein/regenerating protein (PSP/reg) in body fluid samples to assess the severity and prognosis of lower respiratory tract infections, with high levels indicating disease development and severity, and correlating with clinical outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional biomarkers (leukocyte counts, C-reactive protein, procalcitonin) are used for detection and management, then the detection capability is maintained, but the prediction precision of severity and prognosis is insufficient
Solution Approach 1:
The patent introduces a new biomarker parameter (PSP/reg protein levels) to replace or supplement existing biomarkers. By measuring PSP/reg concentration in body fluids, the system achieves more accurate prediction of disease severity and prognosis, directly addressing the insufficiency of conventional biomarkers in providing reliable prognostic information
2Loss of time
If early detection of lower respiratory tract infections is performed, then the timing of diagnosis is improved, but the accuracy of severity prediction remains insufficient with current biomarkers
Solution Approach 1:
The patent measures PSP/reg protein levels as a novel parameter that becomes elevated early in the disease course. This allows simultaneous achievement of early detection (reducing time loss) and accurate severity prediction, as PSP/reg levels correlate with disease severity and can be measured at early stages when conventional biomarkers fail to provide sufficient predictive accuracy
Data Source
AI summary
The present invention relates to a reliable method of prediction of lower respiratory tract infection or inflammation in humans, wherein the level of pancreatic stone protein/regenerating protein (PSP/reg) is determined in serum, and a high level is indicative of the development and the severity of the disease, allowing the classification of patients according to risk.